Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Open-Label Adalimumab in Non-infectious Intermediate, Posterior, or Pan-uveitis
jRCT2080221175Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in uveitis, sponsored by AbbVie Inc.
02
Drugs
03
Conditions
uveitis
Beyond the preview
Go deeper on jRCT2080221175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221175.